Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People with moderate-to-severe plaque psoriasis who are currently being treated with a biologic therapy (a type of medication that targets specific parts of the immune system, such as TNFα antagonists, IL-12/23 antagonists, or IL-17 antagonists)
- People whose doctor is planning to switch their treatment to a medication called tildrakizumab because their current treatment is not working well enough (based on skin score measurements)
- People whose doctor is planning to switch to tildrakizumab because of side effects, an inability to tolerate their current treatment, or a medical reason that prevents its continued use
- People whose doctor is planning to switch to tildrakizumab due to personal preference, difficulty sticking to the current treatment schedule, or other non-medical reasons
- People for whom treatment with tildrakizumab is planned as part of their regular medical care (not specifically for research purposes)
- People who have provided written consent to participate in the study
Who may not be able to join:
- People who are unwilling or unable to follow the study requirements, or whom the investigator determines should not participate
- People who have been treated with 3 or more different biologic therapies in the last 3 years
- People who are already participating in another clinical trial at the same time as this one
- People who have any condition that would prevent a doctor from prescribing tildrakizumab according to its official prescribing guidelines, including any known allergies or bad reactions to the medication
- People who have a close personal or financial relationship with the doctor running the trial (confirm with trial site)
- People who have previously been treated with tildrakizumab
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +43 0 15953960
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score; World Health Organisation Well-Being Index (WHO-5) Score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.